Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Preferred Shares (2025)

Heron Therapeutics (HRTX) has disclosed Preferred Shares for 1 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Preferred Shares changed N/A year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Dec 2025, changed N/A, and an annual FY2025 reading of $1.0 million, changed N/A over the prior year.
  • Preferred Shares was $1.0 million for Q4 2025 at Heron Therapeutics, down from $7.9 million in the prior quarter.
  • Across five years, Preferred Shares topped out at $7.9 million in Q3 2025 and bottomed at $1.0 million in Q4 2025.